Corvus Pharmaceuticals/$CRVS
About Corvus Pharmaceuticals
Ticker
Industry
Employees
CRVS Metrics
$334M
-
-$1.01
1.04
-
Price and volume
Market cap
$334M
Beta
1.04
52-week high
$9.28
52-week low
$1.30
Average daily volume
1.4M
Financial strength
Current ratio
0.925
Quick ratio
0.902
Total debt to equity
2.853
Management effectiveness
Return on assets (TTM)
-28.30%
Return on equity (TTM)
-200.48%
Valuation
Price to book
26.22
Price to tangible book (TTM)
26.22
Price to free cash flow (TTM)
-13.196
Growth
Earnings per share change (TTM)
58.26%
3-year earnings per share growth (CAGR)
78.83%
What the Analysts think about CRVS
Analyst Ratings
CRVS Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
CRVS Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
CRVS News
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
What is the P/E ratio for Corvus Pharmaceuticals stock?
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.